| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
"Phase 2 topline data readout" example | Phase 2 | — | Subscribe to access the data. | Biologics | Digestive System | ||
"Phase 2 topline data readout" example | Phase 2 | — | Subscribe to access the data. | Biologics | Digestive System | ||
"Phase 2 topline data readout" example | Phase 2 | — | Subscribe to access the data. | Biologics | Digestive System |
Recent Updates
Recently added Catalysts
Forte Biosciences, Inc.$43.92
+7.22 (+19.67%)
D 38Pipeline Score Fair Value Biotech · Commercial
Market Cap
423.07 M
EPS
-5.11
P/E Ratio
-
Value Trade
6.11 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
20.32 M
Operating CF
-18.81 M
Total Assets
67.22 M
Total Liabilities
25.12 M
Equity
42.10 M
D/E Ratio
12,345
-7.18 %
Week
-35.22 %
1 Month
-26.79 %
3 Month
5.78 %
6 Month
-97.64 %
5 Year
-99.44 %
All Time
Cash Data
Cash Position
58.22 M
Monthly Burn
6.27 M
Runway
7.3 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
3.19 M
52 Week Range
7.78 - 35.80
% held by Insiders
12.87 %
% held by Institutions
60.7 %
Enterprise Value
364.85 M
Total Shares
12.52 M
Short %
25.19 %
Float Shares
7.51 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Forte Biosciences, Inc.
176Total events
0Upcoming
37Tier-1 (high impact)
2017 – 2026Coverage
Event history 176
Jul 9, 2026
▲Topline ReadoutFB102 Single doseClinical Data
FB102 achieves statistically significant improvement in vitiligo at week 24
vitiligosource ↗
May 11, 2026
▲Fast Track DesignationFB102 Single doseDesignation
FB102 received Fast Track Designation from FDA in celiac disease
celiac diseasesource ↗
May 11, 2026
◆Topline ReadoutFB102 Single doseClinical Data
Topline results from Phase 1b vitiligo study expected shortly
vitiligosource ↗
Apr 2026
▼Equity OfferingCorporate
Raised $172.5 million in gross proceeds through an offering in April 2026
Mar 2026
◆Oral PresentationPresentation
Forte Biosciences to attend Barclays 28th Annual Global Healthcare Conference
Mar 4, 2026
◆Oral PresentationPresentation
Forte Biosciences to present at TD Cowen 46th Annual Healthcare Conference
Feb 11, 2026
◆Oral PresentationPresentation
Forte Biosciences to present at Guggenheim Emerging Outlook: Biotech Summit
Q1 2026
◆Topline ReadoutFB102 Single doseClinical Data
Topline results from FB102 phase 1b vitiligo study expected
vitiligosource ↗
Drug Pipeline Intelligence
D38
Pipeline Score $220M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.7x
rNPV / MCap Top 53%
Micro Cap (rank 430 of 912)
Percentile RankForte Biosciences, Inc. faces pipeline headwinds (38/100), with $1.2B risk-adjusted pipeline value, led by FB-401 in Atopic Dermatitis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FB-401 Monoclonal antibody | Atopic Dermatitis | Phase 2 | NCT04504279 | 26% | $1.1B | COMPLETED | 154 | - | - | Aug 19, 2021 | - | Sep 16, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
FB102 Fast Track | vitiligo | Phase 1b | 2026-07-09 | 29.6% mean improvement in the FVASI score at week 24 (p-value = 0.020) Read More | FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period Read More | |
FB102 Fast Track | vitiligo | Phase 1b | 2026-07-09 | 29.6% mean improvement in the FVASI score at week 24 (p-value = 0.020) Read More | FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period Read More | |
FB102 Fast Track | vitiligo | Phase 1b | 2026-07-09 | 29.6% mean improvement in the FVASI score at week 24 (p-value = 0.020) Read More | FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FBRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
FBRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
FBRX▲ +78.3%on this news· ran to +113% by day 1
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
Forte Biosciences, Inc. reported positive results from its phase 1b study of FB102 for vitiligo. The treatment achieved a 29.6% mean improvement in the FVASI score at week 24, with significant results noted as early as week 9. The study was conducted in a double-blind, placebo-controlled manner.
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES FIRST QUARTER 2026 RESULTS AND PROVIDES UPDATE FB102 Received Fast Track Designation in Celiac Disease DALLAS, TX - MAY 11, 2026 - Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ:
Forte Biosciences, Inc. reported its first quarter 2026 results, highlighting that FB102 received Fast Track Designation from the FDA for celiac disease. The company indicated optimism surrounding the clinical progress of FB102, anticipating key data releases in the near future. Operating expenses rose significantly year-over-year as the company advanced its clinical trials. Despite a reduction in general and administrative expenses, the company continues to report net losses.
Read more →FBRX▼ -6.6%on this newsshared move
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - May 11, 2026
Forte Biosciences, Inc. has announced the issuance of equity inducement awards to a new non-executive employee, as mandated by Nasdaq Listing Rules. The awards consist of options and restricted stock units totaling 100,000 shares, with a vesting schedule over four years. This move aims to attract and retain talent within the company.
Read more →FBRX▲ +8.2%on this newsshared move
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
Forte Biosciences, Inc. has announced its financial results for the first quarter of 2026. The update includes key metrics and performance indicators, although specific details are not provided in the article. The company aims to inform stakeholders about its current position and future outlook.
Read more →FBRX▲ +8.2%on this newsshared move
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Forte Biosciences, Inc. has reported an inducement grant in accordance with Nasdaq listing rules. This announcement highlights the company's compliance with regulatory requirements. However, specific details regarding the nature of the inducement grant were not disclosed in the article.
Read more →FBRX▲ +29%on this news
Forte Biosciences Announces Pricing of $150 Million Public Offering
Forte Biosciences has announced the pricing of a public offering amounting to $150 million. This move is part of the company's strategy to raise funds, although specific details regarding the use of proceeds were not disclosed. The offering is expected to attract investor interest as the company continues to develop its portfolio.
Read more →FBRXForte Biosciences Announces Proposed Public Offering
Forte Biosciences has announced a proposed public offering, but the article lacks substantial details about the offering itself. This absence of information may raise concerns among potential investors regarding the terms and implications of the offering. The announcement seems to have generated a negative sentiment due to the lack of clarity.
Read more →FBRXForte Biosciences, Inc. Announces 2025 Results and Provides Update
Forte Biosciences, Inc. reported its 2025 financial results, highlighting progress in clinical trials for FB102, an anti-CD122 monoclonal antibody. The company anticipates significant data readouts in 2026, particularly for celiac disease, vitiligo, and alopecia areata. Despite increased R&D expenses, Forte maintains a strong cash position, suggesting potential for future growth.
Read more →FBRX▼ -6%on this news
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - March 17, 2026
Forte Biosciences, Inc. has announced the issuance of equity inducement awards to new non-executive employees as part of its compliance with Nasdaq Listing Rules. The grants consist of options to purchase 25,000 shares of common stock, which will vest over four years. This initiative aims to attract talent to support the company's development of its anti-CD122 monoclonal antibody candidate, FB102.
Read more →FBRXForte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. has announced the issuance of equity inducement awards to new non-executive employees as part of its compliance with Nasdaq Listing Rules. A total of 25,000 shares of common stock options will be granted, vesting over four years. This move aims to attract talent to support the company's focus on developing its proprietary therapeutic candidate, FB102.
Read more →FBRXForte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules - March 4, 2026
Forte Biosciences, Inc. has announced the issuance of equity inducement awards to new non-executive employees as part of its compliance with NASDAQ Listing Rules. The grant includes options to purchase 100,000 shares of common stock, which will vest over four years. This move is aimed at attracting talent to support the company's development of its anti-CD122 monoclonal antibody candidate, FB102.
Read more →FBRXForte Biosciences, Inc. to Present at Upcoming Investor Meetings - February 9, 2026
Forte Biosciences, Inc. announced its participation in several upcoming investor meetings. CEO Paul Wagner will present at the Guggenheim Emerging Outlook: Biotech Summit on February 11 and at the TD Cowen 46th Annual Healthcare Conference on March 4. Additionally, he will attend the Barclays 28th Annual Global Healthcare Conference from March 10-12.
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES THIRD QUARTER 2025 RESULTS AND PROVIDES UPDATE Three clinical trial readouts for FB102 expected in 2026, including phase 2 in celiac disease and phase 1b in both vitiligo and alopecia ar
Forte Biosciences, Inc. has announced its third quarter 2025 financial results, highlighting progress in its FB102 program. The company expects three important clinical trial readouts in 2026 for the treatment of celiac disease, vitiligo, and alopecia areata. Despite financial losses growing compared to the previous year, Forte ended the quarter with a strong cash position. Further advancement of FB102 may address significant market opportunities in autoimmune diseases.
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES RESULTS AND PROVIDES UPDATE Three clinical trial readouts for FB102 expected in 2026, including phase 2 in celiac disease and phase 1b in both vitiligo and alopecia areata DALLAS, TX - A
Forte Biosciences, Inc. has announced positive updates regarding its FB102 candidate, with three clinical trial readouts expected in 2026 across celiac disease, vitiligo, and alopecia areata. Following positive results from a phase 1b trial in celiac disease, the company is moving forward with a phase 2 trial. Financial results for Q2 2025 reflected increased research expenditures, contributing to ongoing operating losses. However, the company maintains a robust cash position of $106.1 million to support upcoming trials.
Read more →FBRX▲ +7.7%on this news
FORTE BIOSCIENCES ANNOUNCES PRICING OF $75 MILLION PUBLIC OFFERING DALLAS, TX JUNE 24, 2025 Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related
Forte Biosciences, Inc. has announced the pricing of a public offering involving 5,630,450 shares of its common stock at $12.00 per share, intending to raise approximately $75 million. Alongside the common stock, pre-funded warrants for an additional 619,606 shares are also being offered. The gross proceeds will be allocated for working capital and funding clinical and preclinical research efforts. The offering is set to close around June 26, 2025, pending customary closing conditions.
Read more →FBRX▼ -13%on this newsshared move
FORTE BIOSCIENCES ANNOUNCES POSITIVE DATA IN FB102 CELIAC DISEASE PHASE 1B STUDY Phase 2 Celiac Disease Trial Initiating with Topline Readout Expected in 2026 Forte will be Hosting a Conference Call to Discuss the Result
Forte Biosciences announced promising results from its Phase 1b clinical trial of FB102 for celiac disease, showing significant improvements in various histological and symptomatic endpoints. The study involved 32 subjects and recorded statistically significant benefits for those treated with FB102 compared to placebo. Following these results, the company plans to proceed with a Phase 2 trial of FB102, expected to report topline results by 2026. This marks a notable advancement in their efforts to address unmet needs for patients with celiac disease.
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES RESULTS AND PROVIDES UPDATE DALLAS, TX MAY 15, 2025 Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and au
Forte Biosciences, Inc. reported its first quarter 2025 financial results, showing an increase in research and development expenses due to two ongoing clinical trials for its candidate FB102. Promising updates include no patient dropouts in the celiac disease trial and the initiation of a vitiligo trial. Despite positive progress, the company faces substantial net losses and rising operational costs, but maintains a robust cash position of $45.9 million to support its activities.
Read more →FBRX▼ -10.6%on this news
FORTE BIOSCIENCES, INC. ANNOUNCES RESULTS AND PROVIDES CLINICAL UPDATE DALLAS, TX MARCH 31, 2025 Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoim
Forte Biosciences, Inc. announced positive progress in its clinical trials for FB102, focusing on autoimmune diseases. The year 2024 witnessed the completion of a healthy volunteer study and promising developments in a celiac patient trial. With no dropouts reported, the company expects to share topline results in the second quarter of 2025. Despite a decrease in manufacturing expenses, general and administrative costs increased, leading to a notable rise in net losses per share from the previous year.
Read more →FBRXFORTE BIOSCIENCES FORTE BIOSCIENCES DEC 3, 2024 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain statements contained in this presentation regarding matters that are not historical facts, are forward-lookin
Forte Biosciences highlighted the ongoing development of its product candidate FB102 in its recent presentation. This candidate is designed to modulate immune responses through the IL-2/IL-15 receptor pathways. Although the preclinical data appears promising, the company cautioned that forward-looking statements involve inherent risks and may not guarantee future success. The management team boasts extensive industry experience, potentially bolstering confidence as the company navigates clinical trials and market entry.
Read more →FBRX▲ +128.7%on this news· ran to +171% by day 3
FORTE BIOSCIENCES, INC. ANNOUNCES OVERSUBSCRIBED $53 MILLION PRIVATE PLACEMENT FROM LEADING HEALTHCARE INSTITUTIONAL INVESTORS TO ADVANCE FB102
Forte Biosciences, Inc. has announced an oversubscribed $53 million equity financing, indicating robust support from institutional investors to advance their clinical candidate, FB102. The funds will facilitate the progression of FB102 across autoimmune indications, including a celiac disease trial with results expected in mid-2025. The company plans to host an R&D Day on December 3rd to provide more details about its developments. While the financing reflects strong investor confidence, potential risks related to market conditions and regulatory approvals remain.
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES THIRD QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE DALLAS, TX NOVEMBER 14, 2024 Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical com
Forte Biosciences, Inc. announced its third-quarter results for 2024, highlighting significant advancements in the clinical development of FB102, particularly in a celiac disease trial set to read out data in Q2 2025. The company reported decreased R&D expenses but also noted increased net losses per share compared to the previous year. Despite the positive progress in clinical trials, the decrease in cash reserves raises concerns about the company's financial viability moving forward.
Read more →FBRX▼ -7.8%on this news· ran to -27% by day 1
FORTE BIOSCIENCES, INC. ANNOUNCES SECOND QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE DALLAS, TX AUGUST 14, 2024 Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical comp
Forte Biosciences, Inc. has announced its second quarter 2024 results, highlighting the advancement of its FB102 therapy, which targets autoimmune diseases. The company has successfully completed a phase 1 study demonstrating a good safety profile for FB102. Forte plans to initiate a new patient study focused on celiac disease, with results expected by mid-2025. Financially, the company reported net losses and rising administrative costs, reflecting challenges despite the promising developments in its drug candidate pipeline.
Read more →FBRXIN THE COURT OF CHANCERY OF THE STATE OF DELAWARE CAMAC FUND, LP, Plaintiff, v. PAUL A. WAGNER, LAWRENCE EICHENFIELD, BARBARA K. FINCK, DONALD A. WILLIAMS, STEPHEN K. DOBERSTEIN, STEVEN KORNFELD, SCOTT BRUN, and DAVID GR
A proposed settlement has been reached in the lawsuit Camac Fund, LP v. Wagner, et al., concerning allegations of fiduciary duty breaches related to a private placement. A settlement hearing is scheduled for July 30, 2024, to determine the approval of this agreement. The lawsuit involves significant claims against board members and institutional investors of Forte regarding their actions impacting stockholder elections. The resolution aims to dismiss the claims with prejudice, safeguarding stockholder interests moving forward.
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES FIRST QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE DALLAS, TX MAY 13, 2024 Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company
Forte Biosciences, Inc. announced its financial results for Q1 2024, showing continued progress in the FB102 program for autoimmune diseases. The Phase 1 trial has successfully completed the SAD portion, with the MAD cohorts expected to continue into mid-year. The company reported a net loss increase, but maintains a solid safety profile for FB102 and aims to begin patient-based studies later this year.
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES 2023 RESULTS AND PROVIDES BUSINESS UPDATE DALLAS, TX MARCH 18, 2024 Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on a
Forte Biosciences, Inc. announced its 2023 financial results, reflecting a major milestone in advancing its product candidate FB-102 into the clinic. The company successfully completed the single ascending dose portion of the phase 1 trial. However, operating expenses rose significantly to $32.4 million, with net losses increasing from $13.9 million in 2022 to $31.5 million in 2023. Despite these challenges, Forte ended the year with approximately $37.1 million in cash.
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES $25 MILLION FINANCING AND R&D UPDATE FOR FB-102 -FB-102 Has Demonstrated Potentially Best in Class Activity including Superiority to Standard of Care in GvHD -Proof of Concept Pre-clinic
Forte Biosciences, Inc. has announced a $25 million financing and provided updates on its product candidate FB-102, which shows promising results in treating graft versus host disease (GvHD). FB-102 demonstrated superior efficacy compared to standard treatments in preclinical models, suggesting it may be a best-in-class option. The company plans to advance FB-102 into clinical trials in 2024 and believes it has potential across various autoimmune conditions. Institutional investors have shown significant support for this candidate, reflecting optimism about its market potential.
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES FULL YEAR 2022 RESULTS AND PROVIDES BUSINESS UPDATE -FB-102 Continues to Advance Towards the Clinic DALLAS, TX MARCH 31, 2023 Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX
Forte Biosciences, Inc. announced its full year 2022 results, revealing a transition toward clinical development for its product candidate FB-102, expected to advance by late 2023 or early 2024. The company appointed David Gryska to its Board of Directors, enhancing its leadership with significant industry experience. However, while cash reserves remain relatively stable, net losses were reported at $13.9 million, and overall research and development expenses decreased notably due to the termination of the FB-401 program. Future expenses for development are expected to rise as they focus on FB-102.
Read more →FBRXMR. DAVID GRYSKA APPOINTED TO FORTE BIOSCIENCES BOARD OF DIRECTORS -Addition of Mr. David Gryska Further Strengthens Forte Board of Directors DALLAS, TX JANUARY 12, 2023 Forte Biosciences, Inc. ( www.fortebiorx.com ) (NA
Forte Biosciences, Inc. has appointed David Gryska to its Board of Directors, enhancing the board's expertise in biotechnology and strategic transactions. Gryska brings over 30 years of experience from positions at Incyte and Celgene, among others. He expressed excitement about contributing to the team's efforts in driving long-term shareholder value and advancing Forte's pipeline development. Forte's CEO commended Gryska's extensive background and the value he adds to the company.
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES THIRD QUARTER 2022 RESULTS AND PROVIDES BUSINESS UPDATE -FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications -Leadership
FORTE BIOSCIENCES, INC. ANNOUNCES THIRD QUARTER 2022 RESULTS AND PROVIDES BUSINESS UPDATE -FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications -Leadership Strengthened with the Appointment of Scott Brun, M.D. to
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES SECOND QUARTER 2022 RESULTS AND PROVIDES BUSINESS UPDATE -Forte Biosciences is Developing a Novel Pipeline for the Treatment of Autoimmune Diseases- -Leadership Strengthened with Appoint
FORTE BIOSCIENCES, INC. ANNOUNCES SECOND QUARTER 2022 RESULTS AND PROVIDES BUSINESS UPDATE -Forte Biosciences is Developing a Novel Pipeline for the Treatment of Autoimmune Diseases- -Leadership Strengthened with Appointments of Hubert Chen, M.D. as Chief Scientific Officer an
Read more →FBRX▲ +10.2%on this news
Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President DALLAS (BUSINESS WIRE) Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical c
Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and WIRE) Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases announces that Dr. Hubert Chen, MD has joined t
Read more →FBRX▼ -8.9%on this news
FORTE BIOSCIENCES, INC. ANNOUNCES FIRST QUARTER 2022 RESULTS AND PROVIDES BUSINESS UPDATE -Forte Biosciences to Develop Novel Pipeline for the Treatment of Autoimmune Diseases- -Leadership Strengthened with Appointments
FORTE BIOSCIENCES, INC. ANNOUNCES FIRST QUARTER 2022 RESULTS AND PROVIDES BUSINESS UPDATE -Forte Biosciences to Develop Novel Pipeline for the Treatment of Autoimmune Diseases- -Leadership Strengthened with Appointments of Stephen Doberstein, Ph.D. and Barbara Finck, M.D.to the
Read more →FBRXCLINICAL TRIAL OF FB-401 FOR THE TREATMENT OF ATOPIC DERMATITIS FAILS TO MEET STATISTICAL SIGNIFICANCE TORRANCE, CA SEPTEMBER 2, 2021 Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopha
CLINICAL TRIAL OF FB-401 FOR THE TREATMENT OF ATOPIC DERMATITIS FAILS TO MEET STATISTICAL SIGNIFICANCE TORRANCE, CA SEPTEMBER 2, 2021 Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES FIRST QUARTER 2021 RESULTS AND PROVIDES A GENERAL BUSINESS UPDATE TORRANCE, CA MAY 10, 2021 Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceuti
FORTE BIOSCIENCES, INC. ANNOUNCES FIRST QUARTER 2021 RESULTS AND PROVIDES A GENERAL BUSINESS UPDATE TORRANCE, CA MAY 10, 2021 Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces first quarter 2021 results and provide
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES 4Q AND FULL YEAR 2020 RESULTS AND PROVIDES A GENERAL BUSINESS UPDATE TORRANCE, CA MARCH 24, 2021 Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmace
FORTE BIOSCIENCES, INC. ANNOUNCES 4Q AND FULL YEAR 2020 RESULTS AND PROVIDES A GENERAL BUSINESS UPDATE TORRANCE, CA MARCH 24, 2021 Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces fourth quarter and full year 2020
Read more →FBRXFORTE BIOSCIENCES TOPICAL LIVE BIOTHERAPEUTIC FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASE CORPORATE PRESENTATION NOVEMBER 2020 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain statements contained in this
TREATMENT OF INFLAMMATORY SKIN DISEASE CORPORATE PRESENTATION NOVEMBER 2020Exhibit 99.1 FORTE BIOSCIENCES TOPICAL LIVE BIOTHERAPEUTIC FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASE CORPORATE PRESENTATION NOVEMBER 2020 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES THIRD QUARTER 2020 RESULTS AND PROVIDES GENERAL BUSINESS UPDATE TORRANCE, CA NOVEMBER 9, 2020 Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceu
FORTE BIOSCIENCES, INC. ANNOUNCES THIRD QUARTER 2020 RESULTS AND PROVIDES GENERAL BUSINESS UPDATE TORRANCE, CA NOVEMBER 9, 2020 Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced third quarter 2020 financial
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES FULL PUBLICATION OF PHASE 1/2 DATA IN SCIENCE TRANSLATIONAL MEDICINE TORRANCE, CA SEPTEMBER 9, 2020 Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopha
FORTE BIOSCIENCES, INC. ANNOUNCES FULL PUBLICATION OF PHASE 1/2 DATA IN SCIENCE TRANSLATIONAL MEDICINE TORRANCE, CA SEPTEMBER 9, 2020 Forte Biosciences, Inc. ( www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the publication in Sci
Read more →FBRXFORTE BIOSCIENCES, INC. Audited Financial Statements For the years ended
FORTE BIOSCIENCES, INC. Audited Financial Statements For the years ended December 31, 2019 and December 31, 2018 FORTE BIOSCIENCES, INC. INDEX TO FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm FBRX-2 Balance Sheets as of December 31, 2019 and
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES SECOND QUARTER 2020 RESULTS AND PROVIDES GENERAL BUSINESS UPDATE TORRANCE, CA AUGUST 10, 2020 Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceu
FORTE BIOSCIENCES, INC. ANNOUNCES SECOND QUARTER 2020 RESULTS AND PROVIDES GENERAL BUSINESS UPDATE TORRANCE, CA AUGUST 10, 2020 Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the second quarter 2020 finan
Read more →FBRXCertain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended,
Forte biosciences TOPICAL live biotherapeutic for the treatment of Inflammatory skin disease Corporate PRESENTATION June 2020 Exhibit 99.1 Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within t
Read more →FBRXFORTE BIOSCIENCES, INC. ANNOUNCES CLOSING OF MERGER WITH TOCAGEN To Commence Trading on Nasdaq Capital Market on
FORTE BIOSCIENCES, INC. ANNOUNCES CLOSING OF MERGER WITH TOCAGEN To Commence Trading on Nasdaq Capital Market on June 16, 2020 Under Ticker Symbol FBRX TORRANCE, CA June 15, 2020 Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announce
Read more →FBRXSAN DIEGO
SAN DIEGO - April 23, 2020 - Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, today reported financial results for the first quarter ended March 31, 2020. On February 19, 2020, Tocagen announced it had entered into a definitive a
Read more →FBRXTocagen and Forte Biosciences Announce Merger Transaction to Create Nasdaq-listed Company Focused on Advancing Forte s Late-Stage Clinical Program for Atopic Dermatitis $14 Million to be Invested by Alger, BVF Partners L
Tocagen and Forte Biosciences Announce Merger Transaction to Create Nasdaq-listed Company Focused on Advancing Forte s Late-Stage Clinical Program for Atopic Dermatitis $14 Million to be Invested by Alger, BVF Partners LP, and OrbiMed Prior to the Closing of the Transaction Co
Read more →FBRXTocagen Reports Fourth Quarter and Full Year 2019 Financial Results Definitive merger agreement with Forte Biosciences announced
Tocagen Reports Fourth Quarter and Full Year 2019 Financial Results Definitive merger agreement with Forte Biosciences announced February 19, 2020 SAN DIEGO - February 27, 2020 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reporte
Read more →FBRXForward-Looking Statements This presentation contains forward-looking statements about Tocagen Inc. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "sug
A Cancer-Selective Gene Therapy Company Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements about Tocagen Inc. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests,
Read more →FBRXTocagen Reports Third Quarter 2019 Financial Results and Business Updates
Tocagen Reports Third Quarter 2019 Financial Results and Business Updates SAN DIEGO - Nov. 12, 2019 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the third quarter ended Septem
Read more →FBRXTocagen Announces Restructuring to Focus on Clinical Development Toca 5 full results to be presented at the upcoming Society For Neuro-Oncology Annual Meeting SAN DIEGO - OCTOBER 3, 2019 - Tocagen Inc. (Nasdaq: TOCA), a
Tocagen Announces Restructuring to Focus on Clinical Development Toca 5 full results to be presented at the upcoming Society For Neuro-Oncology Annual Meeting SAN DIEGO - OCTOBER 3, 2019 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, tod
Read more →FBRXTocagen Reports Second Quarter 2019 Financial Results and Business Updates
Tocagen Reports Second Quarter 2019 Financial Results and Business Updates SAN DIEGO - August 8, 2019 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the second quarter ended Jun
Read more →FBRXTocagen Reports First Quarter 2019 Financial and Business Results
Tocagen Reports First Quarter 2019 Financial and Business Results SAN DIEGO - May 7, 2019 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the first quarter ended March 31, 2019.
Read more →FBRXTocagen Reports Fourth Quarter and Full Year 2018 Financial and Business Results
Tocagen Reports Fourth Quarter and Full Year 2018 Financial and Business Results SAN DIEGO - February 27, 2019 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter
Read more →FBRXTocagen Announces Proposed Public Offering of Common Stock
Tocagen Announces Proposed Public Offering of Common Stock SAN DIEGO, December 11, 2018 (GLOBE NEWSWIRE) Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that it has commenced an underwritten public offering of 3,000,000 shar
Read more →FBRXTocagen Reports Third Quarter 2018 Financial and Business Results
Tocagen Reports Third Quarter 2018 Financial and Business Results SAN DIEGO - Nov. 8, 2018 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the third quarter ended September 30, 2
Read more →FBRXTocagen Reports Second Quarter 2018 Financial and Business Results -Strong execution of Toca 5 Phase 3 clinical trial with upcoming milestones on track- -Projected year-end 2018 cash position increased to approximately $
Tocagen Reports Second Quarter 2018 Financial and Business Results -Strong execution of Toca 5 Phase 3 clinical trial with upcoming milestones on track- -Projected year-end 2018 cash position increased to approximately $70 million- SAN DIEGO - Aug 7, 2018 - Tocagen Inc. (Nasda
Read more →FBRXTocagen Reports First Quarter 2018 Financial and Business Results
Tocagen Reports First Quarter 2018 Financial and Business Results SAN DIEGO - May 10, 2018 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the first quarter ended March 31, 2018.
Read more →FBRXTocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater China Region Tocagen eligible to receive up to $127 million in upfront payment, development and commercial mile
Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater China Region Tocagen eligible to receive up to $127 million in upfront payment, development and commercial milestones, plus additional double-digit tiered sales royalti
Read more →FBRXTocagen Reports Fourth Quarter and Full Year 2017 Financial and Business Results
Tocagen Reports Fourth Quarter and Full Year 2017 Financial and Business Results SAN DIEGO - March 8, 2018 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and
Read more →FBRXTocagen Reports Third Quarter 2017 Financial and Business Results SAN DIEGO - Nov. 8 , 2017 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results for the
Tocagen Reports Third Quarter 2017 Financial and Business Results SAN DIEGO - Nov. 8, 2017 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results for the third quarter ended September 30, 2017 and business highlig
Read more →FBRXTocagen Reports Second Quarter 2017 Financial and Business Results SAN DIEGO - Aug. 9 , 2017 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results for th
Tocagen Reports Second Quarter 2017 Financial and Business Results SAN DIEGO - Aug. 9, 2017 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results for the second quarter ended June 30, 2017 and business highlights
Read more →FBRXTocagen Reports First Quarter 2017 Financial and Business Results Upsized initial public offering completed, raising approximately $97.8 million in gross proceeds SAN DIEGO - May 23 , 2017 - Tocagen Inc. (Nasdaq: TOCA),
Tocagen Reports First Quarter 2017 Financial and Business Results Upsized initial public offering completed, raising approximately $97.8 million in gross proceeds SAN DIEGO - May 23, 2017 - Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, to
Read more →Competitive Position
How FBRX ranks across every disease it competes inCompetitive Position is a premium feature
See how FBRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial